Bessemer Group
DYN icon

Bessemer Group’s Dyne Therapeutics DYN Stock Holding History

Bessemer Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
+97
New +$1.8K ﹤0.01% 2394
2024
Q4 		– Sell
-60
Closed -$2K – 2507
2024
Q3 		$2K Buy
+60
New +$2.39K ﹤0.01% 2189

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Bessemer Group's DYN Position: Q2 2026 in Review

Bessemer Group opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 97 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #2394 among its holdings. This is a return to the name: Bessemer Group previously reported a position in DYN as recently as Q3 2024.

Bessemer Group first reported a position in DYN in Q3 2024 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Bessemer Group held 97 shares of Dyne Therapeutics worth $2K as of Q2 2026.
  • Dyne Therapeutics was a new Bessemer Group position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2394 holding.
  • Bessemer Group first reported a position in Dyne Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.